VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation

Acta Neuropathologica

Volumn 125, Issue 6, 2013, Pages 911-912

  Sperveslage, Jan ^b   Gierke, Midea ^a   Capper, David ^c   Honegger, Jürgen ^a   Sipos, Bence ^b   Beschorner, Rudi ^a   Schittenhelm, Jens ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

A RAF KINASE; AVIDIN; B RAF KINASE; BIOTIN; CD68 ANTIGEN; CORTICOTROPIN; DIAMINOBENZIDINE; HUMAN GROWTH HORMONE; MONOCLONAL ANTIBODY; RAF PROTEIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VE1 MONOCLONAL ANTIBODY;

ARTIFACT REDUCTION; CROSS REACTION; ENZYME ACTIVITY; EXON; FALSE POSITIVE RESULT; GENE ACTIVATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HORMONE SYNTHESIS; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LETTER; MAMMOSOMATOTROPH ADENOMA; ONCOGENE; ONCOGENE BRAF; ONCOGNE ARAF; ONCOGNE CRAF; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SEQUENCE HOMOLOGY; TUMOR CLASSIFICATION;

ADENOMA; COHORT STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MUTANT PROTEINS; MUTATION; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84878562188     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1118-5     Document Type: Letter

References (11)

1. Andrulis M et al (2012) Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 36:1796-1800
2. Bullock M et al (2012) Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 19:779-784
3. Capper D et al (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122:11-19
4. Central Brain Tumor Registry of the United States (2012) statistical report, revised March 23. http://www.cbtrus.org/reports/reports.html
5. Colomba E et al (2013) Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 15:94-100
6. De Martino I et al (2007) B-RAF mutations are a rare event in pituitary adenomas. J Endocrinol Invest 30: RC1-3
7. Ewing I et al (2007) A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 66:348-352
8. Ilie M et al (2013) Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 24:742-748
9. Jeong D et al (2012) Detection of BRAFV600E mutations in papillary thyroid carcinomas by peptide nucleic acid clamp real-time pcr: a comparison with direct sequencing. Korean J Pathol 46:61-67
10. Schindler G et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397-405
11. Ziai J, Hui P (2012) BRAF mutation testing in clinical practice. Expert Rev Mol Diagn 12:127-138